Talzenna (talazoparib)
pCPA File Number:
23360
Negotiation Status:
Active Negotiation
Indication(s):
In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
PC0417-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable